Abstract
The expression of leukocyte alkaline phosphatase (LAP) in neutrophils is reduced in some patients with myelodysplastic syndrome (MDS). We quantitatively assayed for LAP in MDS leukocytes by a flow cytometry based method using a monoclonal antibody raised against human bone alkaline phosphatase. The LAP expression was assayed in blood samples from a group of 46 MDS patients, consisting of 39 patients with refractory anemia (RA), 3 with RA with excess blasts (RAEB), and 4 patients with RAEB in transformation. The percentage of LAP-positive cells was significantly higher in the MDS patients than in the normal subjects and also higher in RA than in RAEB and RAEB in transformation. To investigate the cause of the elevated LAP expression, we measured the serum concentrations of several cytokines. The granulocyte colony-stimulating factor (G-CSF) level was significantly elevated in MDS patients, and the serum G-CSF concentration clearly correlated with the percentage of LAP-positive cells. Thus, the LAP activity in RA is higher than in normal subjects, and G-CSF is thought to be one of the causes stimulating LAP expression in MDS neutrophils.
References
1.
Beutler E: Leukocyte alkaline phosphatase; in Beutler E, Lichtman MA, Coller BS, Kipps TJ (eds): Williams’ Hematology, ed 5. New York, McGraw-Hill, 1995.
2.
Cazzola M, Barosi G, Gobbi PG, Invernizzi R, Riccardi A, Ascari E: Natural history of idiopathic refractory sideroblastic anemia. Blood 1995;71:305–312.
3.
Kantarjian HM, Shtalrid M, Kurzrock R, Blick M, Dalton WT, LeMaistre A, Stass SA, McCredie KB, Gutterman J, Freireich EJ, Talpaz M: Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. Am J Med 1988;85:639–644.
4.
Masuhara K, Suzuki S, Yoshikawa H, Tsuda T, Takaoka K, Ono K, Morris DC, Hsu HH, Anderson HC: Development of a monoclonal antibody specific for human bone alkaline phosphatase. Bone Miner 1992;17:182–186.
5.
Rambaldi A, Masuhara K, Borleri GM, Amaru R, Gianni M, Terao M, Barbui T, Garattini E: Flow cytometry of leukocyte alkaline phosphatase in normal and pathologic leukocytes. Br J Haematol 1997;96:815–822.
6.
Borregaard N, Kjeldsen L, Sengelov H, Diamond MS, Springer TA, Anderson HC, Kishimoto TK, Bainton DF: Changes in subcellular localization and surface expression of L-selectin, alkaline phosphatase, and Mac-1 in human neutrophils during stimulation with inflammatory mediators. J Leukoc Biol 1994;56:80–87.
7.
Rambaldi A, Terao M, Bettoni S, Tini ML, Bassan R, Barbui T, Garattini E: Expression of leukocyte alkaline phosphatase gene in normal and leukemic cells: Regulation of the transcript by granulocyte colony-stimulating factor. Blood 1990;76:2565–2571.
8.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189–199.
9.
McComb RB, Bowers GN, Posen S (eds): Alkaline Phosphatase. New York, Plenum Press, 1979.
10.
Hayhoe FGJ, Quaglino D: Cytochemical demonstration and measurement of leukocyte alkaline phosphatase activity in normal and pathological states by a modified azo-dye coupling technique. Br J Haematol 1958;4:375–385.
11.
Kerst JM, de Haas M, van der Schoot CE, Slaper-Cortenbach ICM, Kleijer M, von dem Borne AEGK, van Oers RHJ: Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: Induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells. Blood 1993;82:3265–3272.
12.
de Haas M, Kerst JM, van der Schoot E, Calafat J, Hack CE, Nuijens JH, Roos D, van Oers RHJ, von dem Borne EGK: Granulocyte colony-stimulating factor administration to healthy volunteers: Analysis of the immediate activating effects on circulating neutrophils. Blood 1994;84:3885–3894.
13.
Verhoef GE, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA: Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 1992;6:1268–1272.
14.
Gale RE, Wainscoat JS: Clonal analysis using X-linked DNA polymorphisms. Br J Haematol 1993;85:2–8.
15.
Okamoto T, Okada M, Wada H, Kanamaru A, Kakishita E, Hashimoto T, Furuyama J: Clonality analysis of hematopoietic cells using the polymerase chain reaction amplifying a novel polymorphic site of X chromosome. Am J Hematol 1998;58:263–266.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
